Physician profile
Gemlyn George
NPI 1336496785
$7,572.01
in general payments reported to CMS, 2019-2025
16 companies · $3,285 in 2025
The $3,285 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.03 · 2020: $125 · 2021: $208 · 2022: $558 · 2023: $2,916 · 2024: $384 · 2025: $3,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,890 · Food and Beverage: $1,475 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,890.00 |
| Food and Beverage | $1,474.57 |
| Education | $220.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,375.61 | 2022-2025 | |
| Agios Pharmaceuticals, INC. | $2,339.27 | 2022-2025 | Pyrukynd |
| Astrazeneca Pharmaceuticals Lp | $443.67 | 2020-2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $408.54 | 2023-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $291.65 | 2023 | Promacta |
| Novo Nordisk INC | $125.00 | 2021 | |
| Seagen INC. | $116.96 | 2023 | |
| Global Blood Therapeutics, INC. | $112.94 | 2022 | |
| Janssen Biotech, INC. | $99.00 | 2025 | Darzalex, Talvey, Tecvayli |
| Celgene Corporation | $97.03 | 2019 | |
| Karyopharm Therapeutics INC. | $82.72 | 2021 | |
| Pfizer INC. | $65.62 | 2023 | |
| Incyte Corporation | $14.00 | 2025 | Niktimvo, Jakafi |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gemlyn George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.